HONG KONG, 23rd August, 2016 – Abbott Informatics’ Manager of Global Strategy, Mr. Randy Hice, joins Cedrus Investments’ (“Cedrus”) Life Sciences Advisory Board.
Randy is recognized worldwide as a leading authority in laboratory informatics, specifically focused on complex, large-scale implementation of Laboratory Information Management Systems (LIMS), Laboratory Information Systems (LIS), Electronic Laboratory Notebook (ELN), and sophisticated Cloud architectures. He has been working in the field of laboratory automation since 1984, first as a programmer/analyst at Digital Equipment Corporation, then as a Principal with Laboratory Expertise Center. In 1989, he pioneered Laboratory Workflow Analysis as a methodology for system selection, project planning, harmonization, and system design. With STARLIMS Corporation purchasing Laboratory Expertise Center in 2008 and STARLIMS being acquired subsequently, he now serves as the Manager of Global Strategy for Abbott Informatics where his focus is on complex business analysis, harmonization, inter-operational platforms, Clinical LIS, and Cloud Computing. He is also responsible for analyzing global market potential, demand and profitability for complex informatics systems.
Randy has developed global laboratory automation and harmonization strategies for leading pharmaceutical, biotechnology, medical device, and Contract Research Organization (CRO) companies, identifying opportunities to share and utilize critical laboratory data across corporate locations in Europe, Asia, and the U.S.
As the manager of the Strategic Consulting group of Abbott Informatics, Randy assumed the visionary role of leading the Cloud Services initiative in which he developed service offerings in Infrastructure as a Service (IaaS) and Software as a Service (SaaS) areas to meet the growing demand for Cloud applications.
Randy is the most published author in the world of laboratory automation and workflow analysis, and has served as the monthly Laboratory Automation editor for the Scientific Computing magazine since 1996. He has also contributed to American Pharmaceutical Review and American Laboratory.
Cedrus Investments has been investing in and providing financial advisory services to the life sciences industry for over a decade. In recent years, the firm has been assisting Australian and European life sciences companies to increase their visibility with a broad pool of institutional investors in the Greater China region. At the same time, Cedrus also helps Chinese biopharmaceutical companies and investors to identify valuable overseas investment opportunities.
Mr. Hice said, “I am delighted to join the Cedrus’ Life Sciences Advisory Board. I look forward to sharing my expertise and experience with the Cedrus’ team to identify and evaluate exciting investment opportunities.”
Mr. Rani Jarkas, Chairman of Cedrus Investments extended his welcome and said, “We are excited to have Mr. Randy Hice joined our Life Sciences Advisory Board. As a reputable figure in laboratory informatics, Randy is an ideal addition to the board. His decades of experience and in-depth knowledge will be invaluable to both Cedrus’ direct investments and its investor clients from across the globe. In addition, Randy’s global connections and business development skills in the industry also solidify Cedrus’ unique position in identifying early opportunities to maximize investment returns.”
Rani Jarkas, the Chairman of Cedrus Investments.
Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas